Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacy “Gag Clause” Bills: Another Simple Fix For Drug Pricing That Is Not So Simple

Executive Summary

US Congress wants to prohibit contracts that prevent pharmacists from alerting customers to opportunities to save money by paying out of pocket. Legislation is moving rapidly, but once again, a simple fix to a drug pricing issue may have unintended consequences.

You may also be interested in...



Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics

Legislation headed to President Trump would also ban pharmacy "gag" clauses.

Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics

Legislation headed to President Trump would also ban pharmacy "gag" clauses.

PBMs’ Impact On Drug Prices Probed By House Committee Leaders

Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.

Related Content

Topics

UsernamePublicRestriction

Register

PS123853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel